A project led by IBMB-CSIC tests molecules that stop the cytokine storm caused by SARS-CoV-2 Blog Post

A team of researchers led by Timothy Thomson’s group from the Barcelona Institute of Molecular Biology (IBMB-CSIC), based at the Barcelona Science Park, has developed a platform that allows to see in real-time if a drug inhibits the immune cellular response caused by SARS-CoV-2 infection. The project has the advantage that all the molecules being tested are previously known drugs and compounds that are used for other clinical indications. This would expedite the necessary procedures to propose, in due course, the use in patients with COVID-19.

 

SOM Biotech identifies eravacycline as an effective treatment against SARS-CoV-2 Blog Post

The biopharmaceutical company SOM Biotech,based in the Barcelona Science Park, announces the preclinical validation studies of eravacycline as an effective treatment against SARS-CoV-2. The conclusions of the studies will be presented at the virtual event IDWeek 2020. that will be held from October 21 to 25. Eravacycline is one of the three drugs that the company has identified and validated in collaboration with Ewha Womans University for the treatment of the new coronavirus, and SOM already plans to carry out a Phase 2 clinical trial.